SPS
NVCR icon

Susquehanna Portfolio Strategies’s NovoCure NVCR Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.52M Sell
139,700
-149,659
-52% -$1.87M 0.02% 555
2025
Q4 		$3.74M Buy
289,359
+262,609
+982% +$3.37M 0.06% 359
2025
Q3 		$346K Buy
26,750
+7,750
+41% +$104K 0.01% 906
2025
Q2 		$338K Buy
+19,000
New +$331K 0.01% 733

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Susquehanna Portfolio Strategies's NVCR Position: Q1 2026 in Review

Susquehanna Portfolio Strategies reduced its NovoCure (NVCR) stake by 52% in Q1 2026, selling an estimated $1.87M and leaving 139,700 shares worth $1.52M. The position accounts for 0.02% of the portfolio, ranked #555.

Susquehanna Portfolio Strategies first reported a position in NVCR in Q2 2025 and has held it in 4 quarters since. The position peaked at $3.74M in Q4 2025. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Susquehanna Portfolio Strategies held 139,700 shares of NovoCure worth $1.52M as of Q1 2026.
  • Susquehanna Portfolio Strategies sold 149,659 NovoCure shares in Q1 2026, an estimated $1.87M.
  • NovoCure made up 0.02% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #555 holding.
  • Susquehanna Portfolio Strategies first reported a position in NovoCure in Q2 2025 and has held it in 4 quarters since.
  • Susquehanna Portfolio Strategies's NovoCure position peaked at $3.74M in Q4 2025.
  • 223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.